


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405-252		Serial No. 10/008,062	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)							
				Applicants: David Rizzieri et al.			
				Filing Date October 19, 2001		Group 1642	
U. S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
amh	1.	4,474,893	10/02/84	Reading	436	547	07/01/81
↓	2.	4,676,980	06/30/87	Segal et al.	424	85	19/23/85
↓	3.	4,816,567	03/28/89	Cabilly et al.	530	387	04/08/83
↓	4.	5,624,659	04/29/97	Bigner et al.	424	1.49	02/22/95
FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Subclass	Translation Yes No		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
amh	5.	Aeschlimann et al., <i>Identification of Gln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes</i> , J Biol Chem., 267:11316-21 (1992).					
↓	6.	Akabani et al., <i>Dosimetry of ¹³¹I-Labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors</i> , J Nucl Med., 40:631-638 (1999).					
amh	7.	Back et al., <i>Tenascin expression in activated lymphatic cells and gastrointestinal tracts</i> , Verh Dtsch Ges Pathol (1996) 80:326 (in German) (with English abstract).					
amh	8.	Bell WR, <i>The fibrinolytic system in neoplasia</i> , Sem Throm Hemostat., 22:459-478 (1996).					
amh	9.	Bigner et al., <i>Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial of results</i> , J Clin Oncol, 16:2202-2212 (1998).					
↓	10.	Birchall et al., <i>A microcomputer algorithm for solving first-order compartmental involving recycling</i> , Health Physics, 56:857-868 (1989).					
↓	11.	Bourdon et al., <i>Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody</i> , Cancer Res, 43:2796-2805 (1983).					


EXAMINER

amh

DATE CONSIDERED

6/28/2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-252	Serial No. 10/008,062
LIST OF DOCUMENTS CITED BY APPLICANT		Applicants: David Rizzieri et al.	
 (Use several sheets if necessary)		Filing Date October 19, 2001	Group 1682
12.	Broll et al., <i>Expression of tenascin in tumors of the esophagus, small intestine and colorectum</i> , Gen Diag Pathol, 141:111-119 (1995).		
13.	Bullard et al., <i>In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies</i> , J Neurosurg 64:257-262 (1986).		
14.	Bullard et al., <i>Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs)</i> , Nuklearmedizin-Nuclear Med, 25:210-215 (1986).		
15.	Folkman, J., <i>Anti-angiogenesis: new concept for therapy of solid tumors</i> , Ann. Surg., 175:409-416 (1972).		
16.	Forsberg et al., <i>Skin wounds and severed nerves heal normally in mice lacking tenascin-C</i> , Proc Natl Acad Sci USA, 93:6594-6599 (1996).		
17.	Harris et al., <i>A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group</i> , Blood:1361-1392 (1994).		
18.	Harris et al., <i>Growth factors and angiogenesis in breast cancer</i> , Recent Results in Cancer Research, 127:35-41 (1993).		
19.	He et al., <i>Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin</i> , J. Neuroimmunol., 52:127-137 (1994).		
20.	Hettasch et al., <i>Tissue transglutaminase expression in human breast cancer</i> , Lab. Invest., 75:637-645 (1996).		
21.	Huse, M., <i>Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda</i> , Science, 246:1275-1281 (1989).		
22.	Jahkola et al., <i>Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis</i> , Int J Cancer, 69:445-447 (1996).		
23.	Jallo et al., <i>Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis</i> , Neurosurgery, 41:1052-1059 (1997).		
24.	Kawakatsu et al., <i>Human carcinoma cells synthesize and secrete tenascin in vitro</i> , Jpn J Cancer Res. 83:1073-1080 (1992).		
25.	Kojima et al., <i>Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells</i> , J Cell Biol., 121:439-448 (1993).		
26.	Kostianovsky et al., <i>Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions</i> , Ultrastructural Pathol, 21:537-544 (1997).		
27.	Kusagawa et al., <i>Expression and degradation of tenascin-C in human lung cancers</i> , British J Cancer, 77:98-102 (1998).		
28.	Mackie EJ, <i>Molecules in focus: tenascin-C</i> , Int J Biochem Cell Biol, 29:1133-1137 (1997).		
29.	Mackie et al., <i>Regulation of tenascin-C expression in Bone Cells by TGF-β</i> , Bone, 22:301-307 (1998).		
30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, <i>National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas</i> , Cancer, 49:2112-2135 (1982).		
31.	Reist et al., <i>Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent</i> , Clinical Cancer Research., 4:2495-2502 (1998).		
32.	Ribatti et al., <i>Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study</i> , Eur J. Haematology, 56:45-53 (1996).		

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

EXAMINER *Am Harri*

DATE CONSIDERED 6/28/2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT.**

Sheet

1

of

一

10/008.062

October 19, 2001

David Rizzieri

~~1619~~ 1642

Unknown

5405.252

Examiner
Initials*

Cite No.

U.S. Patent Document

Number

Kind Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

Pages, Columns, Lines,
Where Relevant Passages
or Relevant Figures
Appear

1

5,624,659

Biqner et al.

4/29/1997

Examiner
Initials*

Cite
No.

Foreign Patent Document

Office

Number

Kind Code
(if known)Name of Patentee or
Applicant of Cited
Document

Date of Publication
of Cited Document
MM-DD-YYYY

Pages, Columns, Lines,
Where Relevant
Passages or Relevant
Figures Appear

T

Examiner
Initials*Cite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

1

2

Chilosi, Marco, et al., *Constitutive Expression of Tenascin in T-Dependent Zones of Human Lymphoid Tissues*, American Journal of Pathology, Vol. 143, No. 5, pp. 1348-1355 (November 1993)

3

Rizzieri, D. A., et al., *Markers of Angiogenesis, Factor VIII and Tenascin, Correlate with Disease Activity in Patients with Non-Hodgkin's Lymphoma*, Abstract, Blood, Vol. 94, No. 10, Part 2, Supp. 1, page 4339 (15 November 1999)

△

Rizzieri, D.A., et al., *Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma*, Abstract. Blood. Vol. 98, No. 11, Part 2, pp. 247b (16 November 2001)

2

International Search Report, International Application No. PCT/US01/46104

COPY OF PAPERS
ORIGINALLY FILED

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.